Roche Launches AXELIOS 1, A Next-Generation Sequencing Platform Combining Accuracy, Speed, Scalability And Cost Efficiency For Research Laboratories

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBF

0.00

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHVF

0.00
  • AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications.
  • Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours.
  • The AXELIOS 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.